Pathogenic/Likely Pathogenic Somatic <i>CDK12</i> Mutations in Black Men With Prostate Cancer-Reference-Cited by-同舟云学术

Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer

Published:2023-08-17 Issue:11 Volume:28 Page:e1127-e1128
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Sartor Oliver¹²^ORCID,Jang Albert¹³,Ledet Elisa¹

Affiliation:

1. Tulane Cancer Center, Tulane University , New Orleans, LA , USA

2. Medical Oncology, Mayo Clinic , Rochester, MN , USA

3. Department of Medicine, Division of Hematology and Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center , Cleveland, OH , USA

Abstract

Considering recently published data, this letter to the editor highlights the clinical relevance of CDK12 pathogenic or likely pathogenic mutations, noting that Black men have prostate cancers with increased rates of this pathologic alteration. Practitioners should be made aware of recent findings, given that CDK12 mutations are known to be associated with aggressive variants of prostate cancer and that they may confer susceptibility to PD-1 antagonists.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/28/11/e1127/52772330/oyad240.pdf

Reference5 articles.

1. Actionable genomic alterations in prostate cancer among Black and White United States veterans;Valle,2023

2. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide;Jang,2023

3. CDK12 pathogenic mutations in African American and White patients with prostate cancer;Ledet,2023

4. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis;Sivakumar,2023

5. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors;Antonarakis,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Reply to “Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer”;The Oncologist;2023-09-14